EMBARK Data Support Delandistrogene Moxeparvovec for DMD Across All Study End Points
Over a 52-week treatment period, the gene therapy demonstrated robust evidence for a clinically meaningful benefit, including across several prespecified functional secondary end points vs placebo.
Source: ajmc.com